AI assistant
ANGIODYNAMICS INC — Director's Dealing 2019
Jul 19, 2019
32939_dirs_2019-07-19_33bb86e8-c557-4b4e-96a0-14c8e04bc8ac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2019-07-17
Reporting Person: Boucher Brent J. (SVP and GM of Oncology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-17 | Common Stock | A | 3226 | — | Acquired | 16769 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-07-17 | Non-Qualified Stock Option (right to buy) | $21.54 | A | 10790 | Acquired | 2029-07-17 | Common Stock (10790) | Direct |
Footnotes
F1: This acquisition of 3,226 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,226 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023.
F2: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023.